Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness
The Study of Rituximab in the Treatment of Severe Aplastic Anemia With Platelet Transfusion Refractoriness
Institute of Hematology & Blood Diseases Hospital, China
20 participants
Feb 23, 2023
INTERVENTIONAL
Conditions
Summary
Due to long-term dependence on platelet transfusion, some severe aplastic anemia (SAA) patients suffer platelet transfusion refractoriness (PTR). Unlike immune thrombocytopenia (ITP), glucocorticoids and human immunoglobulin (IVIg) are generally ineffective for PTR. Due to the lack of effective intervention methods, patients with PTR suffer increased platelet transfusions, bleeding events and treatment costs, prolonged hospital stays, and decreased survival rate. SAA with PTR has become a challenge for physicians. The experiment aims to explore the efficacy of rituximab in the treatment of SAA with PTR, and establish a new effective, safe treatment method with relatively low treatment cost.
Eligibility
Inclusion Criteria4
- Initial diagnosed SAA with PTR
- Age\>18 years old, regardless of gender
- Initial diagnosed SAA with PTR
- Age\>18 years old, regardless of gender
Exclusion Criteria8
- Allergy to rituximab
- Severe active infection
- Hypogammaglobulinemia
- Pregnant and lactating women
- Heart failure (NYHA classification IV)
- Individuals with epilepsy, dementia, and other mental disorders that require medication treatment who cannot understand or follow the research protocol
- Chronic infections or other chronic diseases that may be risk to the experiment
- The researchers believe that it is not suitable for participants
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Rituximab is administered at a dose of 100mg per week, a total of 4 times. Cyclosporin is administered at a dose of 3-5mg/kg per day.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06254560